Videos

The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

The advent of biologics has transformed care for patients with inflammatory bowel disease.

Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.

After more promising long-term data, Apellis announced plans to seek regulatory approval. An investigator explains what value it could bring to patients.

Approximately 60% of patients with ulcerative colitis treated with guselkumab achieved clinical remission.

New data on FT218 will be presented at the World Sleep 2022 conference in Rome.

Dr. Avidan speaks of the increased prevalence of insomnia and sleep-wake patterns and promising new therapies for sleep disorders including narcolepsy.

Dr. Garcia-Molina speaks to how smart bed technology can unobtrusively collect data to predict and track the development of symptoms associated with respiratory illnesses.

The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.

The Johns Hopkins expert details recent advances in remote cardiovascular care and research, and explains how the field will continue to evolve.

By blocking certain neurogenic changes that occur in the lungs at childhood, patients may avoid asthma and allergic responses into adulthood.

Currently, antibiotics comprise roughly 80% of prescribed pregnancy medications, and recent epidemiological studies have indicated a link between antibiotic use and dysbiosis.

Dr. Mathias noted that investigators are continuing to determine if age plays a role in peanut allergy risk and sensitization.

The study found that PARTICS, in addition to the usual care these patients received, reduced severe asthma exacerbations by 15.4% (p50.048) which corresponded to a reduction of 13 exacerbations/100 patient-years.

Most cases had onset after 4 hours and were mild, which Dr. Anvari noted should not contraindicate future COVID-19 vaccine doses.

To date, dupilumab is the only biologic medicine to show positive, clinically meaningful phase 3 results in adults and adolescents with EoE.

Dr. McKeon speaks of how patients can be more involved with managing their asthma and allergies by avoiding exposures in their own homes.

Though telemedicine has improved upon school-based asthma programs across the country, Dr. Phipatanakul notes that the adoption of these programs can be difficult to implement.

Dr. Trivedi speaks of a new text-based program that helps provide asthma care to children from communities of color, as well as how COVID-19 affected school-based asthma programs.

Dr. Zein speaks of the relationship between eosinophil count and COVID-19 illness and mortality, especially as it related to inhaled corticosteroid use.

With the field already booming with capability, a Penn Medicine expert discusses her team's research into finding the right tools for the right patients and clinicians.

An executive with Seqirus discusses the company's work to address age-related flu severity risks.

A pilot trial from Perelman showed patients were far more likely to provide blood pressure levels via text than a standard online patient portal.

A look into the research and prospects Seqirus looks to fulfill with the technology platofrm.

There is concerns over missed early screenings for gastrointestinal cancers due to the COVID-19 pandemic.

Dr. Chovatiya returns to speak of some of the changes regarding the study of skin of color that have occurred in recent years.

Investigator Andrew T. Chan, MD, MPH, discusses his team's recent findings showing a positive link between primary care providers per capita and community vaccination rates.